摘要
他克莫司是一种从筑波链霉菌(Streptomyces tsukubaenis)发酵产物中分离得到的23元大环内酯类抗生素,临床上主要作为治疗器官移植后排斥反应的免疫抑制剂。介绍了他克莫司的药物动力学和药效学、理化性质、免疫抑制机制及其生物合成的研究进展。随着他克莫司的合成基因簇的阐释及其代谢途径的解析,运用基因工程和代谢工程手段对其进行的研究逐渐增加。由于其在临床治疗中具有重要地位,使得他克莫司产业的发展具有显著的社会效益和经济价值。
Tacrolimus is a 23-membered macrolide antibiotic isolated from the fermentation production of Streptomyces tsukubaenis.Clinically,it is mainly used as an immunosuppressive agent for treating rejection after organ transplantation.This review introduces the research progress on pharmacokinetics,pharmacodynamics,physicochemical properties,immunosuppressiv-e mechanisms and biosynthesis of tacrolimus.With the interpretation of the synthetic gene cluster of tacrolimus and the analysis of its metabolic pathway,the research using genetic engineering and metabolic engineering was gradually increased.Due to its important position in clinical treatment,promoting the development of industrial production for tacrolimus has significant social and economic benefits.
作者
金美英
方晨捷
陈燏
张博
刘平
柳志强
JIN Meiying;FANG Chenjie;CHEN Yu;ZHANG Bo;LIU Ping;LIU Zhiqiang(East China Pharmaceutical Group Co.,Ltd.,Hangzhou 310011,China;College of Biotechnologyand Bioengineering,Zhejiang University of Technology,Hangzhou 310014,China)
出处
《发酵科技通讯》
CAS
2020年第1期37-43,57,共8页
Bulletin of Fermentation Science and Technology
基金
浙江省科技重点研发计划(2019C03087)。
关键词
他克莫司
筑波链霉菌
免疫抑制
合成基因簇
代谢途径
tacrolimus
Streptomyces tsukubaenis
immunosuppressive
synthetic gene cluster
metabolic pathway
作者简介
金美英(1982-),女,浙江平湖人,研究方向为微生物发酵,E-mail:jinmy@hdpharm.com;通信作者:柳志强,教授,E-mail:microliu@zjut.edu.cn。
